Acadia Pharma (ACAD) Tops Q4 EPS by 5c

Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.42), $0.05 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $121.01 million versus the consensus estimate of $123.2 million.

“Acadia delivered strong financial results in the fourth quarter and full year 2020, driven by robust sales of NUPLAZID in Parkinson’s disease psychosis. Additionally, we made significant advancements in two Phase 3 programs and further expanded our pipeline in pain and neuropsychiatry through strategic business development,” said Steve Davis, Chief Executive Officer. “In 2021, we are focused on delivering continued growth of NUPLAZID, the upcoming potential approval and launch of pimavanserin for dementia-related psychosis and advancing our business development strategy.”

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.

You May Also Be Interested In

• Cloudflare Inc. (NET) PT Raised to $330 at Citizens on Infrastructure Subsector Strength
• Cloudflare Inc. (NET) PT Raised to $330 at Citizens on Infrastructure Subsector Strength
• Stifel Positive on HAYW: 'given the significant underperformance post the announcement which we view positively'